Research and practice in thrombosis and haemostasis · 2026
Outcomes of catheter-directed mechanical thrombectomy in patients with cancer-associated pulmonary embolism: a multicenter, prospective registry.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Banaszkiewicz Marta, Sławek-Szmyt Sylwia, Stępniewski Jakub, Kurzyna Paweł, Klotzka Aneta, Kuliczkowski Wiktor, Klaudel Jacek, Lewandowski Maciej, Grabka Marek, Roik Marek, Waligóra Marcin, Mroczek Ewa, Łomiak Michał, Darocha Szymon, Krasiński Zbigniew, Torbicki Adam, Kopeć Grzegorz, Araszkiewicz Aleksander, Kurzyna Marcin
Аннотация
BACKGROUND: Cancer-associated pulmonary embolism (PE) is a commonplace complication that contributes to morbidity and mortality. Data of catheter-directed mechanical thrombectomy (CDMT) in patients with cancer are limited.
OBJECTIVES: To assess the efficacy and safety of CDMT in patients with intermediate-high or high-risk PE and cancer comorbidity.
METHODS: Multicenter prospective, observational study of 290 PE patients treated with CDMT using continuous vacuum aspiration thrombectomy systems. Patients were classified into 2 groups: oncologic patients (OP) and nononcologic patients (NOP). The primary safety endpoints included in-hospital all-cause mortality and procedure-related major bleeding. The primary efficacy endpoint was the change in right-to-left-ventricle (RV/LV) ratio before and 48 hours after CDMT. The efficacy and safety of CDMT were compared between OP and NOP.
RESULTS: Active cancer was observed in 18.3% (53/290) of patients with PE treated with CDMT. OP did not differ significantly from NOP in terms of baseline characteristics. After treatment, both OP and NOP demonstrated RV/LV ratio reduction by 27% (the mean change of -0.37 ± 0.22 (P < .001) in OP vs -0.31± 0.21 (P < .001) in NOP, P = .166). Major bleeding occurred in 1.9% (1/53) of OP and in 0.8% (2/237) of NOP (P = .455). The rate of all-cause in-hospital mortality reached 9.4% (5/53) in OP and 6.4% within NOP (P = .383).
CONCLUSIONS: CDMT in OP characterized an acceptable safety profile and substantial improvement in RV function, similar to those observed in NOP. Patients with cancer-related PE had similar in-hospital survival rate compared with patients without cancer, when treated with CDMT.
OBJECTIVES: To assess the efficacy and safety of CDMT in patients with intermediate-high or high-risk PE and cancer comorbidity.
METHODS: Multicenter prospective, observational study of 290 PE patients treated with CDMT using continuous vacuum aspiration thrombectomy systems. Patients were classified into 2 groups: oncologic patients (OP) and nononcologic patients (NOP). The primary safety endpoints included in-hospital all-cause mortality and procedure-related major bleeding. The primary efficacy endpoint was the change in right-to-left-ventricle (RV/LV) ratio before and 48 hours after CDMT. The efficacy and safety of CDMT were compared between OP and NOP.
RESULTS: Active cancer was observed in 18.3% (53/290) of patients with PE treated with CDMT. OP did not differ significantly from NOP in terms of baseline characteristics. After treatment, both OP and NOP demonstrated RV/LV ratio reduction by 27% (the mean change of -0.37 ± 0.22 (P < .001) in OP vs -0.31± 0.21 (P < .001) in NOP, P = .166). Major bleeding occurred in 1.9% (1/53) of OP and in 0.8% (2/237) of NOP (P = .455). The rate of all-cause in-hospital mortality reached 9.4% (5/53) in OP and 6.4% within NOP (P = .383).
CONCLUSIONS: CDMT in OP characterized an acceptable safety profile and substantial improvement in RV function, similar to those observed in NOP. Patients with cancer-related PE had similar in-hospital survival rate compared with patients without cancer, when treated with CDMT.